No abstract available.
Prostate* ; Prostate-Specific Antigen*

No abstract available.
Prostate-Specific Antigen

No abstract available.
Immunoassay ; Prostate ; Prostate-Specific Antigen

No abstract available.
Humans ; Male ; Prostate* ; Prostate-Specific Antigen*

No abstract available.
Humans ; Male ; Prostate* ; Prostate-Specific Antigen*

PURPOSE: It is important to know for transurethral resection of prostate (TURP) affecting the serum prostate specific antigen (PSA) value how long one should wait before being able to ~ obtain an accurate and meaningful serum PSA level. We evaluated the change of serum PSA concentration in patients with benign prostate hypertrophy(BPH) before and after TURP in association with time course and resected prostatic weight. MATERIALS AND METHOD: The effect of TURP was examined in 27 patients with BPH (mean age: 64 years; range: 55-79 years). The serum PSA levels were measured serially (before and 1, 3, 5, 7, 14, 30, 60, 90 days after TURP) by Abott IMX assay. RESULTS: The level of serum PSA appeared to be consistent with prostatic volume by transrectal ultrasonography(TRUS) and was elevated by about 0.16 ng/mL for each gram of hyperplastic tissue present (p=0.375, p=0.058). TURP caused an immediate elevation in the serum PSA concentration, with a median increase of 19 ng/mL (p=0.0001). The larger resected group showed a dramatic and statistically significant PSA rise immediately after TURP than the smaller resected group (p=0.023). From the 15 post-operative day, the PSA concentrations continued slightly lower than that of pre-operative day (p=0.0001), and was still decreased on 30 days (p=0.0001). The median time to return to a baseline level of PSA was 30 days (range: 1460 days) after TURP. CONCLUSION: These findings indicate that TURP caused an immediate increase in the serum PSA level, which generally return to stable, baseline level within 30 days. However, because in some patients the serum PSA still remained elevated than upper normal limit after 30 days, it is recommended that a serum PSA determination should be obtained for at least 60 days after TURP.
Humans ; Hypertrophy* ; Prostate* ; Prostate-Specific Antigen* ; Transurethral Resection of Prostate*

PURPOSE: It is important to know for transurethral resection of prostate (TURP) affecting the serum prostate specific antigen (PSA) value how long one should wait before being able to ~ obtain an accurate and meaningful serum PSA level. We evaluated the change of serum PSA concentration in patients with benign prostate hypertrophy(BPH) before and after TURP in association with time course and resected prostatic weight. MATERIALS AND METHOD: The effect of TURP was examined in 27 patients with BPH (mean age: 64 years; range: 55-79 years). The serum PSA levels were measured serially (before and 1, 3, 5, 7, 14, 30, 60, 90 days after TURP) by Abott IMX assay. RESULTS: The level of serum PSA appeared to be consistent with prostatic volume by transrectal ultrasonography(TRUS) and was elevated by about 0.16 ng/mL for each gram of hyperplastic tissue present (p=0.375, p=0.058). TURP caused an immediate elevation in the serum PSA concentration, with a median increase of 19 ng/mL (p=0.0001). The larger resected group showed a dramatic and statistically significant PSA rise immediately after TURP than the smaller resected group (p=0.023). From the 15 post-operative day, the PSA concentrations continued slightly lower than that of pre-operative day (p=0.0001), and was still decreased on 30 days (p=0.0001). The median time to return to a baseline level of PSA was 30 days (range: 1460 days) after TURP. CONCLUSION: These findings indicate that TURP caused an immediate increase in the serum PSA level, which generally return to stable, baseline level within 30 days. However, because in some patients the serum PSA still remained elevated than upper normal limit after 30 days, it is recommended that a serum PSA determination should be obtained for at least 60 days after TURP.
Humans ; Hypertrophy* ; Prostate* ; Prostate-Specific Antigen* ; Transurethral Resection of Prostate*

This study was aimed to investigate the possible correlations between International Prostate Symptom Score (IPSS), volume of total and transition zone of prostate, and serum prostate specific antigen (PSA) level in 42 patients diagnosed and treated as benign prostatic hyperplasia. We got IPSS by interview and calculated the volume of the total and the transition zone (TZ vol) of prostate by transrectal ultrasonography. The size of the total prostate was 37.35+/-12.9 cc (mean+/-standard deviation) and that of the transition zone was 17.72 +/- 10.04 cc. Transition zone index(transition zone volume/total prostate volume, TZ index) was calculated and its value was 0.45 +/- 0.14. Symptom score was not correlated with total prostate volume, TZ volume or 72 index (r=0.27, p>0.05; r=0.23, p>0.05; r=0.16, p>0.05, respectively). Either it did not show correlation with serum PSA level (r=0.16, p>0.05). However, there were statistically significant correlations among serum PSA, total volume, TZ volume, TZ index (r=0.66, p<0.05; r=0.64, p<0.05; r=0.47, p<0.05). From these results, it is difficult to find significant correlations between symptom severity easured by IPSS and several clinical indices such as total prostate volume, transitional volume, TZ index or serum PSA level. Prospective study including developing a more objective symptom scoring system is needed to get a more useful clinical index reflecting the symptom severity of the BPH patients as well as clinical status of them.
Humans ; Prostate* ; Prostate-Specific Antigen ; Prostatic Hyperplasia* ; Ultrasonography*

PURPOSE: The prostate specific antigen, PSA, may be elevated in patients with benign prostatic diseases. Prostatic calculi are very common, but little is known for their effect on the level of PSA. The relationship between prostatic calculi and PSA were analyzed. MATERIALS AND METHODS: A total of 486 patients were evaluated with transrectal an ultrasound (TRUS), and the PSA determined. The patients were divided into the calculi (n=198, 40.6%) and non calculi groups (n=288, 59.4%), according to the presence of prostatic calculi in the TRUS. These groups were further divided into low PSA (PSA<4ng/ml) (n=417) and high PSA groups (PSA=4ng/ml) (n=69), according to serum PSA levels. The prostatic calculi volume was calculated using a transrectal ultrasonographic volume determination, based on the HWL principle (HeightxWidthxLengthx pi/6). RESULTS: The mean volume of the prostatic calculi was 257mm3, which was correlated with the age (p<0.01). The median serum PSA concentration was 2.11ng/ml for all the patients: 2.16ng/ml for the calculi group and 2.08ng/ml for the non-calculi group. The serum PSA concentration was higher in the calculi group, but there was no statistical significant between the two groups (p>0.05). The serum PSA concentration was not correlated with the calculi volume (p>0.05). The difference in the proportion of patients with prostatic calculi was not statistically significant between the low and high PSA groups (p>0.05). The mean volumes of prostatic calculi were 264 and 214mm3 in the low and high PSA groups, respectively, but these were not significantly different between the two groups (p>0.05). CONCLUSIONS: The presence, or volume, of prostatic calculi, as detected by TRUS, has no significant effect on the serum PSA level.
Calculi* ; Humans ; Prostate* ; Prostate-Specific Antigen* ; Prostatic Diseases ; Ultrasonography*

The relationship between the serum values of prostate-specific antigen (PSA) and the histologic composition of benign prostatic hyperplasia (BPH) was investigated in 32 symptomatic BPH patients undergoing transurethral resection of the prostate. We evaluated the free and total PSA concentrations by ACS-PSA2 (Ciba-Corning) assay. The stereological analysis was made by computer aided-area densitometry using H & E stained slides to quantify stromal and glandular areas in the resected prostate tissue. The total PSA concentration versus percentage of glandular area (%G) and stromal-glandular ratio (SGR) correlated significantly (p<0.05 for both) whereas the free PSA concentration and free/total PSA ratio did not (p>0.05 for both). These data suggest that total PSA is directly correlated with the histologic composition of the prostate in men with BPH, however, the proportion of free to total PSA was not informative to predict the histology. Thus, pretreatment evaluation of total PSA would be useful as part of an evaluation method of BPH for medical therapy.
Densitometry ; Humans ; Male ; Prostate ; Prostate-Specific Antigen* ; Prostatic Hyperplasia*